High-grade Serous Ovarian Carcinoma Clinical Trials in Nashville, Tennessee

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer